Literature DB >> 8905076

Live attenuated varicella vaccine.

A M Arvin1, A A Gershon.   

Abstract

Varicella-zoster virus (VZV) is a ubiquitous human pathogen that causes varicella, commonly called chicken pox; establishes latency; and reactivates as herpes zoster, referred to as shingles. A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella. The vaccine induces persistent immunity to VZV in healthy children and adults. Immunization against VZV also has the potential to lower the risk of reactivation of latent virus. The varicella vaccine may eventually reduce or eliminate herpes zoster, which is a serious problem for elderly and immunocompromised individuals.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8905076     DOI： 10.1146/annurev.micro.50.1.59

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN： 0066-4227            Impact factor:   15.500


  17 in total

1.  Occupational risk of infection by varicella zoster virus in Belgian healthcare workers: a seroprevalence study.

Authors:  G Vandersmissen; G Moens; R Vranckx; A de Schryver; P Jacques
Journal:  Occup Environ Med       Date:  2000-09       Impact factor: 4.402

2.  Identification of an important immunological difference between virulent varicella-zoster virus and its avirulent vaccine: viral disruption of dendritic cell instruction.

Authors:  Cindy Gutzeit; Martin J Raftery; Matthias Peiser; Karsten B Tischer; Martina Ulrich; Melanie Eberhardt; Eggert Stockfleth; Thomas Giese; Andreas Sauerbrei; Craig T Morita; Günther Schönrich
Journal:  J Immunol       Date:  2010-06-04       Impact factor: 5.422

3.  Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.

Authors:  S Mallory; M Sommer; A M Arvin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Rapid genotyping of varicella-zoster virus vaccine and wild-type strains with fluorophore-labeled hybridization probes.

Authors:  V N Loparev; K McCaustland; B P Holloway; P R Krause; M Takayama; D S Schmid
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

Review 5.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

6.  Sequencing of 21 varicella-zoster virus genomes reveals two novel genotypes and evidence of recombination.

Authors:  Roland Zell; Stefan Taudien; Florian Pfaff; Peter Wutzler; Matthias Platzer; Andreas Sauerbrei
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

Review 7.  Herpes simplex virus-1 and varicella-zoster virus latency in ganglia.

Authors:  Bradley M Mitchell; David C Bloom; Randall J Cohrs; Donald H Gilden; Peter G E Kennedy
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

8.  Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR.

Authors:  V N Loparev; T Argaw; P R Krause; M Takayama; D S Schmid
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

9.  Vaccination to prevent varicella and shingles.

Authors:  J Breuer
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

10.  Complete DNA sequence analyses of the first two varicella-zoster virus glycoprotein E (D150N) mutant viruses found in North America: evolution of genotypes with an accelerated cell spread phenotype.

Authors:  Charles Grose; Shaun Tyler; Geoff Peters; Joanne Hiebert; Gwen M Stephens; William T Ruyechan; Wallen Jackson; Johnathan Storlie; Graham A Tipples
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.